Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Geron Corp (GERN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 283,504
  • Shares Outstanding, K 186,516
  • Annual Sales, $ 1,070 K
  • Annual Income, $ -27,020 K
  • 60-Month Beta 2.93
  • Price/Sales 265.95
  • Price/Cash Flow N/A
  • Price/Book 1.67

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.09
  • Number of Estimates 1
  • High Estimate -0.09
  • Low Estimate -0.09
  • Prior Year -0.04
  • Growth Rate Est. (year over year) -125.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.48 +4.73%
on 05/17/19
1.94 -20.10%
on 04/29/19
-0.32 (-17.11%)
since 04/24/19
3-Month
1.31 +18.32%
on 03/08/19
2.14 -27.57%
on 04/11/19
+0.09 (+6.16%)
since 02/22/19
52-Week
0.95 +62.30%
on 12/21/18
6.99 -77.83%
on 09/13/18
-3.27 (-67.84%)
since 05/24/18

Most Recent Stories

More News
Geron Announces Two Presentations on Imetelstat at Upcoming European Hematology Association Annual Congress

Geron Corporation (Nasdaq: GERN) today announced that two abstracts containing clinical data and analyses related to imetelstat, the Company's first-in-class telomerase inhibitor, have been accepted for...

GERN : 1.55 (+1.97%)
Geron Provides Imetelstat Program Update

Geron Corporation (Nasdaq: GERN) today provided an update to its 2019 corporate objectives for the imetelstat program.

GERN : 1.55 (+1.97%)
Geron Continues to Build Senior Leadership of Its Development Team

Geron Corporation (Nasdaq: GERN) today announced that it is continuing to build the senior leadership of its development team with the addition of a Vice President, Biometrics, and a Vice President, Manufacturing....

GERN : 1.55 (+1.97%)
Geron's (GERN) Q1 Earnings Beat, Revenues Miss, Stock Up

Geron (GERN) posts narrower-than-expected loss in first-quarter 2019 but misses on revenues. Operating expenses increase on a year-over-year basis.

JNJ : 138.85 (-0.67%)
ALDR : 11.06 (+0.45%)
EDIT : 21.72 (+2.55%)
GERN : 1.55 (+1.97%)
Geron: 1Q Earnings Snapshot

MENLO PARK, Calif. (AP) _ Geron Corp. (GERN) on Thursday reported a loss of $10.1 million in its first quarter.

GERN : 1.55 (+1.97%)
Geron Corporation Reports First Quarter 2019 Financial Results

Geron Corporation (Nasdaq: GERN) today reported financial results for the first quarter ended March 31, 2019. As of the quarter-end, the Company had approximately $170 million in cash and marketable securities,...

GERN : 1.55 (+1.97%)
Geron Expands Senior Leadership of Its Development Team

Geron Corporation (Nasdaq: GERN) today announced an expansion of its development team's senior leadership with the addition of three highly experienced professionals for key functional areas. Their oncology...

GERN : 1.55 (+1.97%)
Healthcare Companies Search for New Ways to Oppose the Spread of Cancer

Cancer is among one of the leading causes of death in the world since many countries are burdened by the lack of access to adequate healthcare, which results in the high number of deaths. In 2018, the...

CRIS : 1.48 (-3.90%)
CVM : 4.74 (+3.27%)
GERN : 1.55 (+1.97%)
SNETD : 0.3900 (+14.71%)
SNET : 0.0102 (-19.69%)
NLNK : 1.89 (+4.42%)
Why International Regulations on Clinical Trials can Actually Reduce Costs and Shorten Time to Market

Every business or industry strives to improve quality, reduce costs and improve their products time to market. This, surprisingly, is true for the biotechnology industry as well. Usually regulations increase...

TEVA : 10.87 (-1.54%)
OPK : 1.96 (+2.08%)
GERN : 1.55 (+1.97%)
GILD : 66.89 (-0.42%)
MBRX : 1.11 (-0.89%)
Latest Biotechnology Advancements may be Key to Unlock new Autism Treatments

According to the Centers for Disease Control, autism affects an estimated 1 in 59 children in the United States today. The Autism Speaks website defines the main problem for researchers/practitioners...

QBIO : 1.5800 (-1.86%)
GERN : 1.55 (+1.97%)
INSM : 26.33 (+1.98%)
PHAS : 10.52 (+6.59%)
CMRX : 3.60 (+2.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade GERN with:

Business Summary

Geron Corporation is a scientific research company that is developing techniques for the health services industry. Their research is currently divided in three different areas. First, they are looking into telomeres and telomerase and their roles in cellular aging and cancer. Second, they are looking...

See More

Key Turning Points

2nd Resistance Point 1.61
1st Resistance Point 1.58
Last Price 1.55
1st Support Level 1.52
2nd Support Level 1.49

See More

52-Week High 6.99
Fibonacci 61.8% 4.68
Fibonacci 50% 3.97
Fibonacci 38.2% 3.26
Last Price 1.55
52-Week Low 0.95

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar